Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601965 · ClinicalTrials.gov registry record · NA
Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
A NA study of Generalized Anxiety Disorder, sponsored by Veterans Medical Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 73
- Enrollment target
- 3
- Study locations
NCT00601965: Completed NA study of Generalized Anxiety Disorder, sponsored by Veterans Medical Research Foundation.
NCT00601965 is a NA study of Generalized Anxiety Disorder that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 73 participants, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (66% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00601965, a NA study of Generalized Anxiety Disorder, has completed, sponsored by Veterans Medical Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.
Primary Outcome
The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score \>= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of \>=5, for a to
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
- BEHAVIORAL Cognitive behavioral therapy (CBT)
Study Locations (3)
California
- UCSD Outpatient Psychiatric Services - San Diego
Missouri
- Washington University - St Louis
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-09 |
| Phase | NA |
What the finished NCT00601965 record still lists
NCT00601965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 213-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00601965 reports a single indexed study location in California, Missouri, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00601965 about?
NCT00601965 is a clinical study titled "Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults". This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.
What is the current status of trial NCT00601965?
This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2007-10. Estimated completion is 2011-09.
What conditions does trial NCT00601965 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00601965?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG), Cognitive behavioral therapy (CBT) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00601965?
This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00601965 being conducted?
This trial has 3 study locations across California, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00601965's enrollment target sits among peer trials
73 32nd of 48 higher than 17 of 48 other Generalized Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Generalized Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
RECRUITING · NA
-
Massage for GAD: Neuroimaging and Clinical Correlates of Response
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia